Advanced search
Publication Cover
Current Eye Research Volume 43, 2018 - Issue 8
Submit an article Journal homepage
239
Views
6
CrossRef citations to date
0
Altmetric
Clinical Trials

Analgesic Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections: A Randomized Crossover Study

Olga E. MakriDepartment of Ophthalmology, Medical School, University of Patras, Patras, Greece
,
Foteini N. TsapardoniDepartment of Ophthalmology, Medical School, University of Patras, Patras, Greece
,
Panagiotis PlotasDepartment of Ophthalmology, Medical School, University of Patras, Patras, Greece
,
Diamanto ArethaDepartment of Anesthesiology and Intensive Care Medicine, Medical School, University of Patras, Patras, Greece
&
Constantinos D. GeorgakopoulosDepartment of Ophthalmology, Medical School, University of Patras, Patras, GreeceCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5646-1370
ORCID Icon
Pages 1061-1064 | Received 15 Sep 2017, Accepted 30 Mar 2018, Published online: 16 Apr 2018

References

  • Tah V, Orlans HO, Hyer J, Casswell E, Din N, Sri Shanmuganathan V,  Ramskold L, Pasu S. Anti-VEGF Therapy and the Retina: an Update. J Ophthalmol. 2015;2015:627674. doi:10.1155/2015/627674.
  • Georgakopoulos CD, Tsapardoni F, Makri OE. Effect of bromfenac on pain related to intravitreal injections: A Randomized Crossover Study. Retina. 2017;37:388–95. doi:10.1097/IAE.0000000000001137.
  • Makri OE, Tsapardoni FN, Pagoulatos DD, Pharmakakis N, Georgakopoulos CD. Diclofenac for pain associated with intravitreal injections: A prospective, randomized, placebo-controlled study. Clin Exp Ophthalmol. 2017;45:867-874. doi:10.1111/ceo.12988.
  • Georgakopoulos CD, Vasilakis PT, Makri OE, Beredima E, Pharmakakis NM. Effect of ketorolac 0.5% drops on patients’ pain perception during intravitreal injection procedure. J Ocul Pharmacol Ther. 2012;28:455–58. doi:10.1089/jop.2012.0023.
  • Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: A meta-analysis. J Clin Pharm Ther. 2017;42:27–38. doi:10.1111/jcpt.12484.
  • Nevanac 0.1% Summary of Product Characteristics. [accessed 2017 May 13]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000818/WC500027158.pdf.
  • Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–97. doi:10.1016/0304-3959(87)91074-8.
  • Faktorovich EG, Melwani K. Efficacy and safety of pain relief medications after photorefractive keratectomy: review of prospective randomized trials. J Cataract Refract Surg. 2014;40:1716–30. doi:10.1016/j.jcrs.2014.08.001.
  • Ozcimen M, Sakarya Y, Goktas S, Sakarya R, Yener HI, Bukus A, Demir LS. Effect of nepafenac eye drops on pain associated with pterygium surgery. Eye Contact Lens. 2015;41:187–89. doi:10.1097/ICL.0000000000000107.
  • Nagpal M, Lambat S, Mehrotra N, Paranjpe G, Yadav H, Bhardwaj S. Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy. Indian J Ophthalmol. 2014;62:606–09. doi:10.4103/0301-4738.129781.
  • Joshaghani M, Nazari H, Ghasemi Falavarjani K, Shokrollahi S, Jafar Ghaempanah M, Abri Aghdam K, Mirbolouk Jalali Z. Effect of Homatropine eye drops on pain after photorefractive keratectomy: A pilot study. Saudi J Ophthalmol. 2013;27:83–85. doi:10.1016/j.sjopt.2012.07.003.
  • Kelly AM. Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain?. Acad Emerg Med. 1998;5:1086–90. doi:10.1111/j.1553-2712.1998.tb02667.x.
  • Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001;38:633–38. doi:10.1067/mem.2001.118863.
  • Ulrich JN. Topical nepafenac after intravitreal injection: A prospective double-masked randomized controlled trial. Retina. 2014;34:509–11. doi:10.1097/IAE.0b013e3182a0e611.
  • Chastain JE, Sanders ME, Curtis MA, Chemuturi NV, Gadd ME, Kapin MA, Markwardt KL, Dahlin DC. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res. 2016;145:58–56. doi:10.1016/j.exer.2015.10.009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.